Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 5132

1.

Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.

Prieux-Klotz C, Dior M, Damotte D, Dreanic J, Brieau B, Brezault C, Abitbol V, Chaussade S, Coriat R.

Target Oncol. 2017 May 24. doi: 10.1007/s11523-017-0495-4. [Epub ahead of print] Review.

PMID:
28540478
2.

Potential role of nutraceutical compounds in inflammatory bowel disease.

Larussa T, Imeneo M, Luzza F.

World J Gastroenterol. 2017 Apr 14;23(14):2483-2492. doi: 10.3748/wjg.v23.i14.2483. Review.

3.

Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies.

Wojciechowski J, Upton RN, Mould DR, Wiese MD, Foster DJR.

AAPS J. 2017 Apr 25. doi: 10.1208/s12248-017-0082-8. [Epub ahead of print]

PMID:
28444562
4.

Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study.

Otake H, Matsumoto S, Mashima H.

Medicine (Baltimore). 2017 Apr;96(16):e6635. doi: 10.1097/MD.0000000000006635.

5.

Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.

Sullivan E, Piercy J, Waller J, Black CM, Kachroo S.

PLoS One. 2017 Apr 14;12(4):e0175826. doi: 10.1371/journal.pone.0175826. eCollection 2017.

6.

Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury.

Pyzik M, Rath T, Kuo TT, Win S, Baker K, Hubbard JJ, Grenha R, Gandhi A, Krämer TD, Mezo AR, Taylor ZS, McDonnell K, Nienaber V, Andersen JT, Mizoguchi A, Blumberg L, Purohit S, Jones SD, Christianson G, Lencer WI, Sandlie I, Kaplowitz N, Roopenian DC, Blumberg RS.

Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2862-E2871. doi: 10.1073/pnas.1618291114. Epub 2017 Mar 22.

7.

Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.

Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN.

Aliment Pharmacol Ther. 2017 May;45(10):1291-1302. doi: 10.1111/apt.14030. Epub 2017 Mar 22. Review.

PMID:
28326566
8.

The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.

Seow CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, Tanyingoh D, Bindra G, Stewart MJ, Beck PL, Kaplan GG, Ghosh S, Panaccione R.

Aliment Pharmacol Ther. 2017 May;45(10):1329-1338. doi: 10.1111/apt.14040. Epub 2017 Mar 20.

PMID:
28318043
9.

Immunology proves a great success for treating systemic autoimmune diseases - a perspective on immunopharmacology: IUPHAR Review 23.

Ishii M.

Br J Pharmacol. 2017 Mar 15. doi: 10.1111/bph.13784. [Epub ahead of print] Review.

PMID:
28299772
10.

Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.

Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro D, Benítez Roldán A, Merino V, Ramírez G, Caunedo Álvarez A, Romero Gómez M.

Dig Dis Sci. 2017 May;62(5):1305-1312. doi: 10.1007/s10620-017-4511-4. Epub 2017 Mar 9.

PMID:
28281165
11.

Modulation of sphingosine-1-phosphate in inflammatory bowel disease.

Peyrin-Biroulet L, Christopher R, Behan D, Lassen C.

Autoimmun Rev. 2017 May;16(5):495-503. doi: 10.1016/j.autrev.2017.03.007. Epub 2017 Mar 7. Review.

PMID:
28279838
12.

The safety of biological pharmacotherapy for the treatment of ulcerative colitis.

Fiorino G, Bonovas S, Cicerone C, Allocca M, Furfaro F, Correale C, Danese S.

Expert Opin Drug Saf. 2017 Apr;16(4):437-443. doi: 10.1080/14740338.2017.1298743. Epub 2017 Mar 10. Review.

PMID:
28279079
13.

The safety of vedolizumab for the treatment of ulcerative colitis.

Novak G, Hindryckx P, Khanna R, Jairath V, Feagan BG.

Expert Opin Drug Saf. 2017 Apr;16(4):501-507. doi: 10.1080/14740338.2017.1300251. Epub 2017 Mar 5. Review.

PMID:
28276855
14.

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment.

Rolandsdotter H, Marits P, Sundin U, Wikström AC, Fagerberg UL, Finkel Y, Eberhardson M.

Int J Mol Sci. 2017 Mar 7;18(3). pii: E575. doi: 10.3390/ijms18030575.

15.

Sarcoidosis associated with infliximab therapy in ulcerative colitis: A case report.

Gîlcă GE, Diaconescu S, Bălan GG, Timofte O, Ştefănescu G.

Medicine (Baltimore). 2017 Mar;96(10):e6156. doi: 10.1097/MD.0000000000006156.

16.

Monoclonal antibodies specific for Bacteroides fragilis enterotoxins BFT1 and BFT2 and their use in immunoassays.

Mootien S, Kaplan PM.

PLoS One. 2017 Mar 3;12(3):e0173128. doi: 10.1371/journal.pone.0173128. eCollection 2017.

17.

Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.

Hindryckx P, Novak G, Vande Casteele N, Khanna R, Laukens D, Vipul J, Feagan BG.

Drugs. 2017 Mar;77(4):363-377. doi: 10.1007/s40265-017-0693-5. Review. Erratum in: Drugs. 2017 Mar;77(4):379.

PMID:
28233275
18.

Crohn's disease complicated by Epstein-Barr virus-driven haemophagocytic lymphohistiocytosis successfully treated with rituximab.

Thompson G, Pepperell D, Lawrence I, McGettigan BD.

BMJ Case Rep. 2017 Feb 22;2017. pii: bcr2016218578. doi: 10.1136/bcr-2016-218578.

PMID:
28228435
19.

Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion.

Cavallaro F, Duca L, Pisani LF, Rigolini R, Spina L, Tontini GE, Munizio N, Costa E, Cappellini MD, Vecchi M, Pastorelli L.

Can J Gastroenterol Hepatol. 2017;2017:6843976. doi: 10.1155/2017/6843976. Epub 2017 Jan 16.

20.

Neutralizing and Targeting Properties of a New Set of α4β7-Specific Antibodies Are Influenced by Their Isotype.

Girard A, Jelicic K, Van Ryk D, Rochereau N, Cicala C, Arthos J, Noailly B, Genin C, Verrier B, Laurant S, Razanajaoana-Doll D, Pin JJ, Paul S.

J Acquir Immune Defic Syndr. 2017 May 1;75(1):118-127. doi: 10.1097/QAI.0000000000001307.

PMID:
28177967

Supplemental Content

Loading ...
Support Center